ProCE Banner Activity

Phase I Study: Ivosidenib (AG-120) in Mutant IDH1 Acute Myeloid Leukemia and Other Advanced Hematologic Malignancies

Slideset Download
Conference Coverage
Ivosidenib, an investigational mutant IDH1 inhibitor, was well tolerated with evidence of activity and durable responses in patients with malignancies harboring mutated IDH1.

Released: December 20, 2017

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

AstraZeneca

Celgene

Genentech TEXT Only

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Pharmacyclics Inc

Seagen

Takeda Oncology